Take­da rests its R&D foot­print on U.S. hubs 

Back in late 2014, when Take­da an­nounced that it had re­cruit­ed Sanofi vet An­drew Plump as head of its R&D group, savvy ob­servers were care­ful to note that Plump would be based in the Japan­ese com­pa­ny’s Boston hub. A few days ago, the Japan­ese phar­ma com­pa­ny un­veiled its $725 mil­lion plan to re­or­ga­nize R&D, pulling out of Cam­bridge, UK while con­cen­trat­ing much of the work in the Boston area. This chart from Take­da helps il­lus­trate what’s go­ing on in R&D, as the phar­ma com­pa­ny looks to ex­pand on its links in the key hub while keep­ing San Diego in play for in­dus­try con­nec­tions on the West Coast. Clear­ly, much of its fu­ture col­lab­o­ra­tive work will be done in the U.S. as CEO Christophe We­ber me­thod­i­cal­ly moves to change the cul­ture at Take­da.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA